# Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention

> **NCT07228663** · PHASE3 · NOT_YET_RECRUITING · sponsor: **McMaster University** · enrollment: 100 (estimated)

## Conditions studied

- Hip Fracture Surgery
- Cardiovascular Prevention
- Venous Thromboembolism (VTE)

## Interventions

- **DRUG:** rivaroxaban and ASA
- **DRUG:** Low-molecular weight heparin
- **DRUG:** Fondaparinux
- **DRUG:** Direct Oral Anticoagulant (DOAC)

## Key facts

- **NCT ID:** NCT07228663
- **Lead sponsor:** McMaster University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2027-07-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-11-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07228663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07228663, "Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07228663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*